A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

ClinicalTrials.gov ID: NCT00477672

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00477672. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 5:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.

Study identification

NCT ID: NCT00477672
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Enrollment: 298 participants

Conditions and interventions

Conditions

Parkinson's Disease Psychosis

Interventions

Pimavanserin tartrate (ACP-103) Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 40 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 2007 (Type not available)
Primary completion: Jun 2009 (Actual)
Completion: Jul 2009 (Actual)
Last update posted: May 17, 2017

2007 – 2009

United States locations

U.S. sites: 36
U.S. states: 18
U.S. cities: 36

Facility	City	State	ZIP	Site status
Not listed	Gilbert	Arizona	85234	—
Not listed	Phoenix	Arizona	85013	—
Not listed	Berkeley	California	94705	—
Not listed	Carson	California	90746	—
Not listed	Fountain Valley	California	92708	—
Not listed	Irvine	California	92697	—
Not listed	Sunnyvale	California	94805	—
Not listed	Danbury	Connecticut	06810	—
Not listed	Fairfield	Connecticut	06824	—
Not listed	Boca Raton	Florida	33486	—
Not listed	Gainesville	Florida	32610	—
Not listed	Jacksonville	Florida	32209	—
Not listed	Miami	Florida	33136	—
Not listed	Pompano Beach	Florida	33060	—
Not listed	Port Charlotte	Florida	33952	—
Not listed	Sarasota	Florida	34239	—
Not listed	St. Petersburg	Florida	33701	—
Not listed	Tampa	Florida	33606	—
Not listed	Augusta	Georgia	30912	—
Not listed	Springfield	Illinois	62794	—
Not listed	Scarborough	Maine	04074	—
Not listed	Worcester	Massachusetts	01655	—
Not listed	Southfield	Michigan	48034	—
Not listed	Traverse City	Michigan	49684	—
Not listed	Toms River	New Jersey	08755	—
Not listed	Kingston	New York	12401	—
Not listed	Rochester	New York	14618	—
Not listed	Asheville	North Carolina	28806	—
Not listed	Salisbury	North Carolina	28144	—
Not listed	Columbus	Ohio	43210	—
Not listed	Warwick	Rhode Island	02886	—
Not listed	Brentwood	Tennessee	37027	—
Not listed	San Antonio	Texas	78258	—
Not listed	Richmond	Virginia	23229	—
Not listed	Kirkland	Washington	98034	—
Not listed	Spokane	Washington	99204	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00477672, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 17, 2017 · Synced Nov 12, 2026